Anzeige
Mehr »
Dienstag, 13.05.2025 - Börsentäglich über 12.000 News
Titan für Raketen, Vanadium für Batterien: Radar-Projekt perfekt für die Industrie-Revolution!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
617 Leser
Artikel bewerten:
(2)

MediThinQ Unveils SCOPEYE 3D Micro Surgery Solution; Chris Lee of VentureBlick Assumes Chairmanship

Finanznachrichten News

SINGAPORE, May 23, 2024 /PRNewswire/ -- MediThinQ, the Korean startup pioneering extended reality (XR) wearable displays for surgical applications, unveils its groundbreaking SCOPEYE 3D Micro Surgery Solution. This innovative microsurgery solution leverages the latest Eyes Up Display technology to enhance precision across medical specialties, revolutionising depth perception and spatial awareness without the need for eyepieces.

The MediThinQ SCOPEYE 3D Micro Surgery Solution

The SCOPEYE 3D Micro Surgery Solution comprises the SCOPEYE Eyes Up wearable display, the 3D Microvision, a light and portable high-performance 3D digital microscope, and the 3D AddON, a device that elevates conventional 2D microscopes to advanced 3D capabilities. Offering exceptional performance, mobility, and space efficiency while maintaining a minimalist design aesthetic, it empowers surgeons to perform 3D procedures wherever needed. Its portability makes it ideal for a wide range of applications, including microsurgery, plastic surgery, dental procedures, ophthalmology, hair transplant surgery, and dermatology.

The benefits of the SCOPEYE 3D Micro Surgery Solution are manifold. With high-resolution 3D optics, surgeons gain unparalleled visual clarity and depth perception, enhancing their precision and accuracy during procedures. Additionally, the solution offers significant cost efficiencies, maximised ergonomic comfort, and advanced features such as 3D recording and training capabilities, further enhancing patient care and surgical outcomes.

Propelling MediThinQ's growth forward, Chris Lee, Founder & CEO of VentureBlick, assumes the role Chairman of the Board of MediThinQ, marking a pivotal moment in MediThinQ's journey. With a remarkable 30-year career spanning top global pharmaceutical and medtech companies, Chris brings extensive experience and leadership to the table.

In a strategic move to deepen their collaboration, MediThinQ and VentureBlick have entered a cross-ownership agreement. With this arrangement, both companies will own stakes in each other's shares, reaffirming their commitment to mutual advancement and success.

MediThinQ and VentureBlick's partnership began when MediThinQ joined VentureBlick's Super Incubator programme. With VentureBlick's support, MediThinQ achieved key milestones. Now, their bond has deepened even further, marking a significant moment for both companies.

Chris Lee, Founder & CEO of VentureBlick said: "MediThinQ's solutions deliver tangible medical value, and we are thrilled to collaborate with them on an even deeper level to enhance surgical visualisation, ultimately leading to improved patient outcomes. Our partnership will accelerate MediThinQ's growth further and pave the way for pioneering advancements in the field of extended reality for surgical applications."

Seungjoon Im, Founder & CEO of MediThinQ, said: "Our SCOPEYE 3D Mirco Surgery Solution sets a new standard and is a strong addition to our offerings as we ramp up our global commercialisation efforts. We're grateful to Chris for accepting the role of Chairman of our Board. With his vast international experience, he is the undoubtedly the ideal person to bring MediThinQ to new heights."

MediThinQ's journey from a visionary startup to a global leader is marked by significant milestones. As the first Asian startup to globally launch XR surgical displays, the company has garnered attention and accolades worldwide. Securing major deals with industry giants in the USA, Japan, Australia, and Europe, is a testament to the quality and effectiveness of MediThinQ's offerings, positioning the company as a frontrunner in the global healthcare landscape.

MediThinQ is currently raising its Series B fund while exploring IPO options in Korea, Singapore, Hong Kong SAR, and North America. It is setting the stage for potential early exits through strategic acquisitions or accelerated commercial growth.

Photo - https://mma.prnewswire.com/media/2415784/The_MediThinQ_SCOPEYE_3D_Micro_Surgery_Solution.jpg

Cision View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/medithinq-unveils-scopeye-3d-micro-surgery-solution-chris-lee-of-ventureblick-assumes-chairmanship-302148815.html

© 2024 PR Newswire
Die USA haben fertig! 5 Aktien für den China-Boom
Die Finanzwelt ist im Umbruch! Nach Jahren der Dominanz erschüttert Donald Trumps erratische Wirtschaftspolitik das Fundament des amerikanischen Kapitalismus. Handelskriege, Rekordzölle und politische Isolation haben eine Kapitalflucht historischen Ausmaßes ausgelöst.

Milliarden strömen aus den USA – und suchen neue, lukrative Ziele. Und genau hier kommt China ins Spiel. Trotz aller Spannungen wächst die chinesische Wirtschaft dynamisch weiter, Innovation und Digitalisierung treiben die Märkte an.

Im kostenlosen Spezialreport stellen wir Ihnen 5 Aktien aus China vor, die vom US-Niedergang profitieren und das Potenzial haben, den Markt regelrecht zu überflügeln. Wer jetzt klug investiert, sichert sich den Zugang zu den neuen Wachstums-Champions von morgen.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche 5 Aktien die Konkurrenz aus den USA outperformen dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.